Company:  AYTU BIOSCIENCE, INC (AYTU)
Form Type:  S-4
Filing Date:  6/8/2020 
CIK:  0001385818 
Address:  373 INVERNESS PARKWAY
SUITE 206
 
City, State, Zip:  ENGLEWOOD, Colorado 80112 
Telephone:  (720) 437-6580 
Fiscal Year:  06/30 
Last Trade
Last Trade: 
$1.25  
Change: 
0.06 (5.04%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$150.77M
Trade AYTU now with

© 2020  
Description of Business
We are a specialty pharmaceutical company focused on identifying, acquiring, and commercializing novel products that address significant patient needs. We have multiple FDA-approved products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs, across a range of conditions, through our in-house commercial team. Our commercial infrastructure consists of a U.S.-based specialty sales force and an international distribution network with presence in approximately fifty countries. We currently are focused on commercialization of four products, (i) Natesto®, a testosterone replacement therapy, or TRT, (ii) Tuzistra®XR, a codeine based antitussive, (iii) ZolpiMistTM, a short-term insomnia treatment and (iv), MiOXSYS®, a novel in vitro diagnostic system for male infertility assessment.
Register and access this filing in:     
  FORM S-4
    CALCULATION OF REGISTRATION FEE
    SUBJECT TO COMPLETION, DATED JUNE 8, 2020
    TABLE OF CONTENTS
    ABOUT THIS PROSPECTUS
    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
    RISK FACTORS
    USE OF PROCEEDS
    DESCRIPTION OF COMMON STOCK
    Transfer Agent and Registrar
    PLAN OF DISTRIBUTION
    WHERE YOU CAN FIND MORE INFORMATION
      INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
    EXPERTS
    LEGAL MATTERS
    PART II
      Item 20. Indemnification of Directors and Officers
      Item 21. Exhibits and Financial Statement Schedules
      Item 22. Undertakings
    SIGNATURES
  EXHIBIT 5.1
  EXHIBIT 23.2
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 23.3
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 23.4
    Consent of Independent Auditors
  EXHIBIT 23.5
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 99.1